AC
Aisling Capital LLC
13F filer · CIK 0001571076Last filed Nov 13, 2019
Inactive · not filing 13F
13F portfolio value$45.3MU.S. long equity reported on 13F
Positions51 new · 0 closed
Net flow last quarter-$16MBuys minus sells
Top 10 positions weight100.0%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q3 2019Reported Nov 13, 20195 positions | |||||
| ATAIMTAimmune Therapeutics, Inc. | $26M | 57.34% | 1.97% | -37.7% | Q3 2015 |
| $16.1M | 35.46% | 6.08% | Not reported | Q4 2014 | |
| CTCDTXCidara Therapeutics, Inc. | $1.78M | 3.93% | 2.70% | -12.7% | Q3 2015 |
| ASTRXCAsensus Surgical, Inc. | $1.48M | 3.27% | Not reported | Not reported | Q2 2014 |
| VVRAYViewRay, Inc. | $0 | 0.00% | 0.02% | Not reported | Q1 2016 |
| Q2 2019Reported Aug 8, 20194 positions | |||||
| ATAIMTAimmune Therapeutics, Inc. | $41.4M | 68.67% | 3.18% | Not reported | Q3 2015 |
| $14M | 23.14% | 6.08% | Not reported | Q4 2014 | |
| ASTRXCAsensus Surgical, Inc. | $3.23M | 5.35% | Not reported | Not reported | Q2 2014 |
| CTCDTXCidara Therapeutics, Inc. | $1.72M | 2.84% | 3.81% | Not reported | Q3 2015 |
| Q1 2019Reported May 7, 20194 positions | |||||
| ATAIMTAimmune Therapeutics, Inc. | $44.5M | 66.84% | 3.19% | Not reported | Q3 2015 |
| $13.7M | 20.55% | 7.78% | Not reported | Q4 2014 | |
| ASTRXCAsensus Surgical, Inc. | $5.69M | 8.55% | Not reported | Not reported | Q2 2014 |
| CTCDTXCidara Therapeutics, Inc. | $2.71M | 4.07% | 3.83% | Not reported | Q3 2015 |
| Q4 2018Reported Feb 11, 20196 positions | |||||
| LOLOXOLoxo Oncology, Inc. | $286M | 80.87% | 6.66% | Not reported | Q3 2014 |
| ATAIMTAimmune Therapeutics, Inc. | $47.6M | 13.48% | 3.20% | Not reported | Q3 2015 |
| $8.62M | 2.44% | 7.78% | Not reported | Q4 2014 | |
| ASTRXCAsensus Surgical, Inc. | $5.4M | 1.53% | Not reported | Not reported | Q2 2014 |
| CTCDTXCidara Therapeutics, Inc. | $2.4M | 0.68% | 3.67% | Not reported | Q3 2015 |
| VVRAYViewRay, Inc. | $2.21M | 0.62% | 0.38% | -79.1% | Q1 2016 |
Premium opens every quarter this fund has filed